Clinical Trials Browser

neratinib × Clear all

NCT06126276 2026-04-22

Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Solid Tumors (A ComboMATCH Treatment Trial)

Phase 2 Recruiting

Other solid neoplasm

Malignant Female Reproductive System Neoplasm

NCT03919292 2026-04-21

Neratinib + Valproate in Advanced Solid Tumors, w/Expansion Cohort in Ras-Mutated Ca

Phase 1/2 Recruiting

Gastrointestinal

Colonic Neoplasms, Pancreatic Neoplasms, Disease Progression

NCT05564377 2026-04-21

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

Phase 2 Recruiting

Fallopian Tube Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Endometrial Neoplasms

NCT03377387 2026-04-16

Capecitabine 7/7 Schedule With Neratinib in Patients With Metastatic HER2-Positive Breast Cancer

Phase 1/2 Active not recruiting

Breast Neoplasms

NCT05372614 2026-04-14

Testing the Safety and Tolerability of the Anti-cancer Drugs Trastuzumab Deruxtecan and Neratinib for Cancers With Changes in the HER2 Gene

Phase 1 Suspended

Neoplasm Metastasis

NCT04886531 2026-04-08

Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers

Phase 2 Recruiting

Breast Neoplasms

NCT01042379 2026-03-13

I-SPY

Phase 2 Recruiting

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

NCT03101748 2026-02-12

Neratinib and Paclitaxel With or Without Pertuzumab and Trastuzumab Before Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Breast Cancer

Phase 1/2 Terminated

34 enrolled 15 charts

Breast Neoplasms, Inflammatory Breast Neoplasms

NCT06109467 2026-02-09

Neratinib In Combination With Chemotherapy/Trastuzumab/Pembrolizumab In HER2 Gastroesophageal Cancer

Phase 2 Recruiting

Gastrointestinal

Stomach Neoplasms

NCT01494662 2026-01-23

HKI-272 for HER2-Positive Breast Cancer and Brain Metastases

Phase 2 Completed

140 enrolled 32 charts

Breast Neoplasms

NCT03289039 2026-01-22

Neratinib +/- Fulvestrant in HER2+, ER+ Metastatic Breast Cancer

Phase 2 Terminated

21 enrolled 15 charts

Breast Neoplasms

NCT05933395 2026-01-20

GERTRUDE

Phase 2 Recruiting

Neoplasm Metastasis

NCT03065387 2026-01-12

Neratinib and Everolimus, Palbociclib, or Trametinib in Treating Participants With Refractory and Advanced or Metastatic Solid Tumors With EGFR Mutation/Amplification, HER2 Mutation/Amplification, or HER3/4 Mutation or KRAS Mutation

Phase 1 Active not recruiting

Neoplasm Metastasis

NCT04374305 2026-01-12

INTUITT-NF2

Phase 2 Active not recruiting

Ependymoma, Meningioma, Neuroma, Acoustic, Neurofibromatosis 2

NCT04965064 2025-12-15

Trial of Neratinib Plus Capecitabine in Subjects With HER2-Negative Metastatic Breast Cancer With Brain Metastases and Abnormally Active HER2 Signaling

Phase 2 Recruiting

Brain Neoplasms, Breast Neoplasms

NCT02932280 2025-12-05

Safety and Dose Finding Study of Neratinib in Children and Young Adults With Cancer That Has Returned or Not Responded to Treatment

Phase 1/2 Active not recruiting

CNSLymphoidOther hematologic neoplasm

Disease, Leukemia, Lymphoma, Recurrence, Central Nervous System Neoplasms

NCT02977780 2025-11-10

INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)

Phase 2 Recruiting

Glioblastoma

NCT06008275 2025-11-10

Neratinib in Combination With Ruxolitinib in Patients With mTNBC

Phase EARLY_PHASE1 Recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05274048 2025-10-29

Neratinib and Fam-Trastuzumab Deruxtecan in Advanced Gastro-esophageal Cancer Patients

Phase 1 Recruiting

Gastrointestinal

Gastrointestinal Neoplasms, Stomach Neoplasms

NCT05760612 2025-09-25

Adjuvant Trastuzumab Plus Neratinib in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer After Neoadjuvant Trastuzumab Plus Pertuzumab

Phase 3 Recruiting

Breast Neoplasms

NCT05919108 2025-09-09

Neoadjuvant Neratinib in Stage I-III HER2-Mutated Lobular Breast Cancers

Phase 2 Recruiting

Carcinoma, Lobular

NCT07152782 2025-09-03

THUNDER

Phase 2 Not yet recruiting

Breast Cancer With Brain Metastasis

NCT04388384 2025-08-06

ELEANOR

Breast Neoplasms

NCT03094052 2025-06-26

Incidence and Severity of Diarrhea in Patients With HER2 Positive Breast Cancer Treated With Trastuzumab and Neratinib

Phase 2 Completed

11 enrolled 12 charts

Breast Neoplasms

NCT07019272 2025-06-13

Neratinib in Extended Adjuvant Treatment for HER2+ Early Breast Cancer With pCR But High-Risk Features: A Hebei Multi-Center Real-World Study

Not yet recruiting

HER2-positive Breast Cancer

NCT05243641 2025-06-11

Neratinib and Capmatinib Combination (Phase Ib/II) in Metastatic Breast Cancer and Inflammatory Breast Cancer Patients With Abnormal HER-family and c-Met Pathway Activity as Measured by the CELsignia Signaling Analysis Test

Phase 1/2 Terminated

10 enrolled 11 charts

Breast Neoplasms

NCT04502602 2025-05-04

iNNOVATE

Phase 1 Active not recruiting

Ovarian Neoplasms

NCT05615818 2025-04-23

SAFIR-ABC10

Phase 3 Recruiting

Gastrointestinal

Biliary Tract Neoplasms

NCT05252988 2025-04-01

DIANER

Phase 2 Active not recruiting

Breast Neoplasms

NCT06083662 2025-03-18

Neratinib and Trastuzumab Biosimilar in Patients with HER2 Mutated Advanced Solid Cancers

Phase 2 Completed

Neoplasm Metastasis

NCT06813079 2025-02-18

Using Tumor Models to Determine Treatments

Phase 2 Not yet recruiting

Gastrointestinal

Carcinoma, Carcinoma, Pancreatic Ductal

NCT05388149 2025-01-31

Kadcyla And Neratinib for Interception of HER2+ Breast Cancer With Molecular Residual Disease

Phase 2 Recruiting

Breast Neoplasms

NCT06693024 2024-11-20

NeraHER2

HER2-positive Breast Cancer

NCT06692491 2024-11-18

SPRING

Phase 2 Not yet recruiting

Rare Tumour

NCT06519110 2024-07-25

CVL009-C2001

Phase 2 Not yet recruiting

GastrointestinalGynecologicHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Salivary Gland Neoplasms, Cholangiocarcinoma

NCT06374888 2024-04-19

Nilatinib Maleate Tablets Combined With Capecitabine in the Treatment of HER2-positive Advanced Esophageal/Esophagogastric Junction/Gastric Adenocarcinoma With Brain Metastases

Phase 2 Not yet recruiting

Brain Neoplasms

NCT01953926 2024-03-12

SUMMIT

Phase 2 Terminated

582 enrolled 27 charts

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis, Neoplasms

NCT03878524 2024-03-04

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

Phase 1 Terminated

BreastClassical hematologyGastrointestinalGenitourinaryLymphoidMyeloidOther hematologic neoplasmPlasma cell

Anemia, Blast Crisis, Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Thrombocytosis, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

NCT03812393 2023-12-18

FACT-2

Phase 2 Unknown

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04901299 2023-08-01

HER2-Signal

Phase 2 Withdrawn

Breast Neoplasms, Neoplasm Metastasis

NCT04781374 2023-07-11

Neratinib in Patients With Metastatic Castration-Resistant Prostate Cancer

Phase 2 Withdrawn

Prostatic Neoplasms

NCT02673398 2023-06-18

Neratinib in Treating Older Patients With Stage IV HER2-Positive Breast Cancer

Phase 2 Completed

25 enrolled 18 charts

HER2 Positive Breast Carcinoma

NCT04366713 2023-02-10

A Study to Characterize Colon Pathology in Patients With HER2 Amplified Breast Cancer Treated With Neratinib

Phase 2 Completed

6 enrolled 8 charts

Breast Neoplasms

NCT02236000 2023-01-26

A Dose-Escalation Study Evaluating the Combination of Trastuzumab Emtansine (T-DM1) With Neratinib in Women With Metastatic HER2-Positive Breast Cancer

Phase 1/2 Completed

49 enrolled 17 charts

Breast Neoplasms

NCT04460430 2022-10-25

NEREA

Phase 2 Terminated

Breast Neoplasms

NCT05491057 2022-08-08

Treatment Patterns of Neratinib in HER2+ EBC in China

Not yet recruiting

Breast Neoplasms

NCT02400476 2022-05-06

An Open-Label Study to Characterize the Incidence and Severity of Diarrhea in Patients With Early-Stage HER2+ Breast Cancer Treated With Neratinib and Loperamide

Phase 2 Completed

563 enrolled 16 charts

Breast Neoplasms

NCT01670877 2022-04-15

Neratinib +/- Fulvestrant in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer

Phase 2 Completed

56 enrolled 29 charts

Breast Neoplasms

NCT03457896 2022-03-31

Study of Neratinib +Trastuzumab or Neratinib + Cetuximab in Patients With KRAS/NRAS/BRAF/PIK3CA Wild-Type Metastatic Colorectal Cancer by HER2 Status

Phase 2 Unknown

Gastrointestinal

Colorectal Neoplasms

NCT04856475 2022-03-02

NeraBrain

Phase 2 Withdrawn

Brain Neoplasms, Breast Neoplasms